Back to News
Market Impact: 0.15
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
Source: PR Newswire
Healthcare & BiotechCompany Fundamentals
VolitionRx announced it will present an abstract at the European Society of Medical Oncology related to its early cancer detection and minimal residual disease (MRD) opportunity. The company cited an estimated $36 billion total addressable market, but the provided announcement contains no clinical-results details, commercialization update, or financial guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
VNRX0.45
More News
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- Biotech stocks are surging. How investors can play the new drug innovation boom
- Braskem creditors, shareholders near deal on $11bn debt restructuring
- Instacart reportedly discussed selling itself with DoorDash and Uber
- Nvidia's role as AI financier faces first big test as neoclouds take market hit
- Trump set to announce plan by Audi to build a U.S. factory in Georgia, source says